GTx raises $43.5M; China's Ascletis inks hep C deal; AntriaBio wipes out milestones in exchange for small payment;

@FierceBiotech: Biotech upstart Sage sees early efficacy for rare brain seizure drug. More | Follow @FierceBiotech

@JohnCFierce: From FierceBiotechResearch: Genentech R&D team fixes a flawed approach to Alzheimer's. Story | Follow @JohnCFierce

> Memphis, TN-based GTx raised $43.5 million in a private stock sale to affiliates of BVF Partners. Release

> China's Ascletis has in-licensed an NS5A hep C treatment from San Francisco-based Presidio Pharmaceuticals. "This licensing agreement for PPI-668 adds a fourth drug candidate in late-stage development to the Ascletis pipeline, which aims to provide innovative therapeutics for important medical needs in China," said Ascletis CEO Jinzi J. Wu. "Based on the clinical data to date, we believe that PPI-668, in combination with our current direct acting antiviral agent, danoprevir or ASC08, which has completed Phase II, offers a potentially effective interferon-free regimen for HCV-infected patients in China." Release

> AntriaBio says it has inked a deal to extinguish $44 million in potential milestone payments in exchange for a $55,000 payment to the bankruptcy estate of PR Pharmaceuticals. Release

Medical Device News

@FierceMedDev: ICYMI: Power morcellation ban unlikely, but other FDA restrictions coming soon; includes email to FDA obtained by FMD. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: The new AstraZeneca, University of Manchester center for drug delivery becomes operational in February. More | Follow @VarunSaxena2

> Microsoft 3-D audio system helps the visually impaired navigate more easily. Story

> Device for minimally invasive treatment of enlarged prostate gains CMS reimbursement. Article

Pharma News

@FiercePharma: FDA tightens reins on equine compounding companies. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI Friday: Fresenius Russian partnership tanks even as Russian tanks spotted rolling into Ukraine. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Eisai 'speechless' after another Fycompa price smack-down from Germany. More | Follow @CarlyHFierce

> J&J eyes dealmaking in China to ratchet up pharma sales. Article

> For sale: Bankrupt Dendreon and its laggard Provenge, for $275M or more. Any takers? More

CRO News

> India's GVK snags an early-stage CRO amid global growth. News

> Charles River deepens its ties to Huntington's R&D with new deal. Item

> FDA taps Icon to help patients better weigh in on trials. Story

> PPD dives into adaptive trials with Medidata deal. Report

> AMRI tanks on disappointing sales and a dimmer outlook. Article

Biotech IT News

> Google steps up Genomics pitch with $25-a-genome storage service. More

> Team taps Wikipedia for flu forecasting data. Story

> Open-source atlas of the human proteome goes live. Article

> FDA resumes its long search for a CIO. More

> AstraZeneca strikes $150M deal to buy data analysis business. Report

Animal Health News

> Jaguar postpones IPO amid rocky market for biotech and animal health offerings. Article

> Merck to meat industry: Zilmax is safe. Item

> FDA tightens reins on equine compounding companies. Report

> MWI shares sink despite better-than-expected earnings. Story

> Zoetis beats estimates on strength of livestock products and allergy drug for dogs. News

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.